[go: up one dir, main page]

WO2004039361A1 - Compositions a liberation intermittente de milnaciprane - Google Patents

Compositions a liberation intermittente de milnaciprane Download PDF

Info

Publication number
WO2004039361A1
WO2004039361A1 PCT/US2003/033685 US0333685W WO2004039361A1 WO 2004039361 A1 WO2004039361 A1 WO 2004039361A1 US 0333685 W US0333685 W US 0333685W WO 2004039361 A1 WO2004039361 A1 WO 2004039361A1
Authority
WO
WIPO (PCT)
Prior art keywords
milnacipran
dose
drug
hours
release
Prior art date
Application number
PCT/US2003/033685
Other languages
English (en)
Inventor
Jane Hirsh
Roman V. Rariy
Michael Heffernan
Original Assignee
Collegium Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collegium Pharmaceutical, Inc. filed Critical Collegium Pharmaceutical, Inc.
Priority to CA002503121A priority Critical patent/CA2503121A1/fr
Priority to MXPA05004422A priority patent/MXPA05004422A/es
Priority to AU2003301762A priority patent/AU2003301762B2/en
Priority to PCT/US2003/033685 priority patent/WO2004039361A1/fr
Priority to EP03809957A priority patent/EP1556024A4/fr
Priority to JP2005501896A priority patent/JP2006506461A/ja
Publication of WO2004039361A1 publication Critical patent/WO2004039361A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Definitions

  • the present invention generally relates to novel milnacipran pulsatile release compositions.
  • SNRIs serotonin and norepinephrine reuptake inhibitors
  • duloxetine (Cymbalta ® , Eli Lilly and Company) was assessed in a pooled analysis of 7 double-blind trials involving 1032 patients treated with duloxetine (40-120 mg/day) and 732 patients treated with placebo.
  • Adverse events which occurred at a rate of more than 5% for duloxetine were nausea, dry mouth, fatigue, dizziness, constipation, somnolence, decreased appetite, and sweating.
  • Adverse events which led to discontinuation of treatment were nausea, dizziness, somnolence, dermatitis, insomnia, headache, and fatigue. Nausea and dizziness led to significantly more duloxetine-treated patients discontinuing treatment, compared with placebo (Mallinckrodt C.
  • an immediate release formulation of milnacipran may not be suitable for a once-daily dosing regimen for a treatment of depression due to milnacipran' s relatively short, approximately 8 hours, half-life (Ansseau M. et al., 1994, Psychopharmacology, 114:131-137). Milnacipran' s half-life could also be responsible for the fact that twice-a-day administration (versus once-a-day) of immediate release formulation in fibromyalgia trial resulted in pain improvement statistically superior to that of placebo treatment (Cypress Bioscience Inc., Cypress Bioscience Inc. Announces Final Results of Milnacipran Phase II Clinical Trial in Fibromyalgia, Media Release, March 21, 2003.
  • a once-a-day oral milnacipran pulsatile release composition has been developed.
  • This pulsatile composition when administered orally, releases drug in spaced apart "pulses".
  • This delivery profile minimizes the exposure of the internal mucosal surfaces to the drug substance and thus reduces milnacipran gastrointestinal side effects such as nausea and vomiting while maintaining therapeutic milnacipran blood plasma levels.
  • this pulsatile composition is ideally suited for the delivery of milnacipran since it has been shown that twice-a-day milnacipran administration results in an enhanced therapeutic response as compared to once-a-day administration.
  • This dosage form provides in vivo drug plasma levels characterized by C max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. These levels help to avoid stimulation of the cholinergic effects on the CNS.
  • the composition delivers milnacipran over approximately 24 hours, resulting in diminished incidence and decreased intensity of common milnacipran side effects such as nausea, vomiting, sleep disturbance, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
  • common milnacipran side effects such as nausea, vomiting, sleep disturbance, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervous
  • the composition provides an initial rapid release of a therapeutically effective dose of milnacipran followed by so-called "delayed release” pulses such that a second and optional third delayed dose of the active agent is released from the dosage form.
  • the dosage form mimics a multiple dosing profile without repeated dosing, i.e., with only a single administration in a day.
  • the dosage form provides a twice daily dosing profile when the dosage form contains both an immediate release dosage unit and a single delayed release dosage unit.
  • the dosage form provides a three times daily dosing profile when the dosage form contains an immediate release dosage unit and two delayed release dosage units.
  • the formulation provides a pulsatile release dosage form for treating conditions responsive to the administration of milnacipran, wherein the dosage form comprises an immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit.
  • the immediate release dosage unit comprises a first dose of an active agent that is released substantially immediately following oral administration of the dosage form to a patient.
  • the delayed release dosage unit comprises a second dose of the active agent and a means for delaying release of the second dose until approximately 3 hours to less than 14 hours following oral administration of the dosage form.
  • the second delayed release dosage unit when present, comprises a third dose of the active agent and a means for delaying release of the third dose until at least 5 hours to approximately 18 hours following oral administration of the dosage form.
  • Each dosage form contains a therapeutically effective amount of active agent.
  • approximately 30 wt. % to 70 wt. %, preferably 40 wt. % to 60 wt. %, of the total amount of active agent in the dosage form is released in the initial pulse, and, correspondingly approximately 70 wt. % to 30 wt. %, preferably 60 wt. % to 40 wt. %, of the total amount of active agent in the dosage form is released in the second pulse.
  • the second pulse is preferably released approximately 3 hours to less than 14 hours, and most preferably approximately 5 hours to 12 hours, following administration.
  • a dosage form comprising a closed capsule housing at least two drug-containing dosage units is used.
  • Each dosage unit comprises two or more compressed tablets, or may be comprised of a plurality of beads, granules or particles, providing that each dosage unit has a different drug release profile.
  • the immediate release dosage unit releases drug substantially immediately following oral administration to provide an initial dose.
  • the delayed release dosage unit releases drug approximately 3 hours to 14 hours following oral admimstration to provide a second dose.
  • an optional second delayed release dosage unit releases drug about 2 hours to 8 hours following the release of the second dose, and is typically 5 hours to 18 hours following oral administration.
  • Another dosage form comprises a compressed tablet having a drug- containing immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit.
  • the immediate release dosage unit comprises a plurality of beads, granules or particles that release drug substantially immediately following oral administration to provide an initial dose.
  • the delayed release dosage unit comprises a plurality of coated beads or granules, which release drug approximately 3 hours to 14 hours following oral administration to provide a second dose.
  • An optional second delayed release dosage unit comprises coated beads or granules that release drug about 2 to 8 hours following administration of the initial delayed release dose, typically 5 to 18 hours following oral administration.
  • the beads or granules in the delayed release dosage unit(s) are coated with a bioerodible polymeric material.
  • This coating prevents the drug from being released until the appropriate time, i.e., approximately 3 hours to less than 14 hours following oral administration for the delayed release dosage unit and at least 5 hours to approximately 18 hours following oral administration for the optional second delayed release dosage unit.
  • the components may be admixed in the tablet or may be layered to form a laminated tablet.
  • Another dosage form is a tablet having a drug-containing immediate release dosage unit, a delayed release dosage unit, and an optional second delayed release dosage unit, wherein the immediate release dosage unit comprises an outer layer that releases the drug substantially immediately following oral administration.
  • the delayed release dosage unit comprises an inner core that is coated with a bioerodible polymeric material.
  • the coating is applied such that release of the drug occurs approximately 3 hours to less than 14 hours following oral administration.
  • the outer layer completely surrounds the inner core.
  • the (first) delayed release dose comprises an internal layer that releases drug approximately 3 hours to less than 14 hours following oral administration.
  • This internal layer is surrounded by the outer layer.
  • the second delayed release dosage unit generally comprises an inner core that releases the drug at least 5 hours to approximately 18 hours following oral administration.
  • the layers of this tablet starting from the external surface
  • the inner core comprises delayed release beads or granules.
  • the internal layer comprises the drug coated with a bioerodible polymeric material.
  • both the delayed release dosage unit and second delayed release dosage units are surrounded by an inner layer. This inner layer is free of active agent.
  • the layers of this tablet (starting from the external surface) comprise an outer layer, inner layer and an admixture of the delayed release dosage units.
  • the first delayed release pulse occurs once the inner layer is substantially eroded thereby /039361
  • the dose corresponding to the (first) delayed release dosage unit is released immediately since the inner layer has prevented access to this dose for the appropriate time, e.g., from approximately 3 hours to 10 hours.
  • the second delayed release dose is formulated to effectively delay release for at least 5 hours to approximately 18 hours following oral administration.
  • the delayed release dose is released approximately 3 hours to less than 14 hours, most preferably approximately 5 hours to 12 hours, following oral administration.
  • the (first) delayed release dose is released approximately 3 to 10 hours, preferably 4 hours to 9 hours, following oral administration.
  • the third dose i.e., the second delayed release dose
  • These drug dosage forms are administered orally and can be used for the treatment of depression, for fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS) such as irritable bowel syndrome (IBS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders (major depressive disorder, dysthymia, atypical depression) and anxiety disorders (generalized anxiety disorder, phobias, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder), premenstrual dysphoric disorder, temperomandibular disorder, atypical face pain, migraine headache, and tension headache.
  • IBS irritable bowel syndrome
  • NCCP noncardiac chest pain
  • functional dyspepsia interstitial cystitis
  • essential vulvodynia essential vulv
  • an active agent includes a single active agent as well as combinations of different active agents
  • a pharmaceutical carrier includes a single pharmaceutical carrier as well as combinations of two or more carriers
  • reference to “a compressed tablet” includes a single as well as a plurality of compressed tablets
  • reference to “an immediate release dosage form” includes a single immediate release dosage form in addition to a group of two or more immediate release dosage forms
  • reference to "a coating” as in “a delayed release coating” includes a single coating as well as two or more coatings, and the like.
  • “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
  • “optional second delayed release dosage unit” when an “optional second delayed release dosage unit" appears in describing the dosage forms, “optional second delayed release dosage unit,” means that the second delayed release dosage unit may or may not be present, and thus, the description includes dosage forms wherein the second delayed release dosage unit is present and dosage forms wherein the second delayed release dosage unit is not present.
  • “about” means approximately plus or minus 10%.
  • the milnacipran composition provides a pulsatile delivery dosage form for administering milnacipran and mimics twice or three times daily dosing of milnacipran. That is, the composition provides an immediate dose followed by one or more pulsatile doses several hours after ingestion of the dosage form.
  • the composition further provides second and, optionally, third drug doses several hours after ingestion of the dosage form. Since milnacipran is known to cause gastrointestinal disturbances, delay of the first dose should substantially reduce exposure of stomach mucosa to the drug and, hence, diminish milnacipran local side effects such as nausea and vomiting.
  • the primary endpoint used by Cypress Bioscience was defined as the change in pain score from baseline to endpoint based on pain scores collected on the patient electronic diary. Endpoint was defined as week twelve for assessments with a single value (such as clinical measures) or the average of scores at weeks 11 and 12 for diary-based outcomes. It was shown that milnacipran effectively treated pain associated with fibromyalgia syndrome and, additionally, improved mood in depressed patients with FMS. The improvement in pain scores reported by study participants, when 200 mg daily dose was reached, indicates that this substantially higher dose than the one typically used for depression treatment is needed to the alleviation of pain.
  • the BID-IR dosing regimen supports drug plasma levels characterized by lower C max and lower drug plasma fluctuations over 24 hour time period than that of QD-IR.
  • C max When a daily dose is administered QD-IR, the C max is approximately twice higher than that of BID-IR dosing regimen. Higher C max causes an increase in the severity of the adverse side effects (that also might interfere with the objective pain level self-assessment by the patient) and leads to a lower drug tolerance and patient compliance. Therefore, the observed superior milnacipran performance when drug was administered BID-IR is thought to be due to more "sustained" drug plasma levels over a 24 hour period.
  • Delayed release dosage form is one that releases a drug (or drugs) at a time other than promptly after administration.
  • Pulsatile release dosage form is one that mimics a multiple dosing profile without repeated dosing and allows at least a twofold reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g. as a solution or prompt drug- releasing, conventional solid dosage form).
  • a pulsatile release profile is characterized by a time period of no release (lag time) followed by rapid drug release. Milnacipran Milnacipran and methods for its synthesis are described in U.S.
  • Milnacipran (midalcipran, midacipran, F 2207) inhibits the uptake of both, norepinephrine (NE) and serotonin (5-HT), with an NE to 5-HT ratio of 2:1 (Moret et al., 1985, Neuropharmacology, 24:1211-1219; Palmier et al., 1989, Eur. J. Clin. Pharmacol., 37:235-238) but does not affect the uptake of dopamine. Milnacipran has no affinity for alpha or beta adrenergic, muscarinic, histaminergic, and dopaminergic receptors.
  • milnacipran has a low potential to produce anticholinergic, sedative, and stimulant effects. Milnacipran does not affect the number of beta adrenoceptors in rat cortex after chronic administration (Briley M. et al., Int. Clin. Psychopharmac, 1996, 11:10-14). Additional information regarding milnacipran may be found in the Merck Index, 12 th Edition, at entry 6281.
  • milnacipran also encompasses pharmaceutically acceptable, pharmacologically active derivatives of milnacipran including both individual enantiomers of milnacipran (dextrogyral and levrogyral enantiomers) and their pharmaceutically acceptable salts, mixtures of milnacipran enantiomers and their pharmaceutically acceptable salts, and active metabolites of milnacipran and their pharmaceutically acceptable salts, unless otherwise noted. It is understood that in some cases dosages of enantiomers, derivatives, and metabolites may need to be adjusted based on relative activity of the racemic mixture of milnacipran.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, tolunesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tarta
  • the pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, p. 704.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • stereoisomers refers to compounds made up of the same atoms bonded by the same bonds but having different spatial structures which are not interchangeable. The three-dimensional structures are called configurations.
  • enantiomers refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
  • optical isomer is equivalent to the term “enantiomer”.
  • racemate refers to a mixture of equal parts of enantiomers.
  • chiral center refers to a carbon atom to which four different groups are attached.
  • enantiomeric enrichment refers to the increase in the amount of one enantiomer as compared to the other. Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column. Choice of the appropriate chiral column, eluent and conditions necessary to effect separation of the enantiomeric pair is well within the knowledge of one of ordinary skill in the art using standard techniques well known in the art, such as those described by J. Jacques, et al., “Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981.
  • the milnacipran can be administered adjunctively with other active compounds such as analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxioltyics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics, and anti-narcoleptics.
  • active compounds such as analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxioltyics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs
  • aceclofenac acetaminophen
  • adomexetine almotriptan
  • alprazolam amantadine
  • amcinonide aminocyclopropane
  • amitriptyline amolodipine
  • amoxapine amphetamine
  • aripiprazole aspirin, atomoxetine, azasetron, azatadine
  • beclomethasone benactyzine, benoxaprofen, bermoprofen, betamethasone, bicifadine, bromocriptine, budesonide, buprenorphine, bupropion, buspirone, butorphanol, butriptyline, caffeine, carbamazepine, carbidopa, carisoprodol, celecoxib, chlordiazepoxide, chlorpromazine, cho
  • Formulations are prepared using a pharmaceutically acceptable
  • carrier composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions.
  • the “carrier” is all components present in the pharmaceutical formulation other than the active ingredient or ingredients.
  • carrier includes but is not limited to diluents, binders, lubricants, desintegrators, fillers, and coating compositions.
  • Carrier also includes all components of the coating composition which may include plasticizers, pigments, colorants, stabilizing agents, and glidants.
  • the delayed release dosage formulations may be prepared as described in references such as "Pharmaceutical dosage form tablets", eds. Liberman et. al.
  • suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit ® (Roth Pharma, Westerstadt, Germany), Zein, shellac, and polysaccharides.
  • Other polymers that can be used include biodegradable polymers such as polyhydroxyacids like poly(lactic acid-glycolic acid), and other approved hydrolytically or enzymatically degradable polymers.
  • the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, pore formers and surfactants.
  • Optional pharmaceutically acceptable excipients present in the drug- containing tablets, beads, granules or particles include, but are not limited to, diluents, binders, lubricants, disintegrants, colorants, stabilizers, and surfactants.
  • Diluents also termed “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules.
  • Suitable diluents include, but are not limited to, for example, dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and powder sugar. Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet or bead or granule remains intact after the formation of the dosage forms.
  • Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, cellulose,including hydorxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, and veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid and polyvinylpyrrolidone.
  • Lubricants are used to facilitate tablet manufacture.
  • suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, and mineral oil.
  • Disintegrants are used to facilitate dosage form disintegration or "breakup" after administration, and generally include, but are not limited to, starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross- linked PNP (Polyplasdone XL from GAF Chemical Corp).
  • starch sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross- linked PNP (Polyplasdone XL from GAF Chemical Corp).
  • Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions.
  • Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
  • Suitable anionic surfactants include, but are not limited to, those containing carboxylate, sulfonate and sulfate ions.
  • anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2- ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
  • nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG- 150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG- 1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, Poloxamer ® 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.
  • amphoteric surfactants include sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the tablets, beads granules or particles may also contain minor amount of nontoxic auxiliary substances such as wetting or emulsifying agents, dyes, pH buffering agents, and preservatives.
  • the amount of active agent released in each dose will be a therapeutically effective amount.
  • the total amount in the dosage form is in the range of approximately 25 to 500 mg.
  • the pharmaceutical dosage forms provide pulsatile delivery of milnacipran.
  • pulsatile is meant that a plurality of drug doses are released at spaced apart intervals of time.
  • release of the initial dose is substantially immediate, i.e., the first drug release "pulse” occurs within about one hour of ingestion.
  • This initial pulse is followed by a first time interval (lag time) during which very little or no drug is released from the dosage form, after which a second dose is then released.
  • a second nearly drug release-free interval between the second and third drug release pulses may be designed. The duration of the nearly drug release-free time interval will vary depending upon the dosage form design e.g., a twice daily dosing profile, a three times daily dosing profile, etc.
  • the nearly drug release-free interval has a duration of approximately 3 hours to 14 hours between the first and second dose.
  • the nearly drug release-free interval has a duration of approximately 2 hours to 8 hours between each of the three doses.
  • the pulsatile release profile is achieved with dosage forms that are closed and preferably sealed capsules housing at least two drug-containing "dosage units" wherein each dosage unit within the capsule provides a different drug release profile. Control of the delayed release dosage unit(s) is accomplished by a controlled release polymer coating on the dosage unit, or by incorporation of the active agent in a controlled release polymer matrix.
  • Each dosage unit may comprise a compressed or molded tablet, wherein each tablet within the capsule provides a different drug release profile.
  • a first tablet releases drug substantially immediately following ingestion of the dosage form
  • a second tablet releases drug approximately 3 hours to less than 14 hours following ingestion of the dosage form.
  • a first tablet releases drug substantially immediately following ingestion of the dosage form
  • a second tablet releases drug approximately 3 hours to less than 10 hours following ingestion of the dosage form
  • the third tablet releases drug at least 5 hours to approximately 18 hours following ingestion of the dosage form. It is possible that the dosage form includes more than three tablets.
  • each dosage unit in the capsule may comprise a plurality of drug-containing beads, granules or particles.
  • drug-containing beads refer to beads made with drug and one or more excipients or polymers.
  • Drug-containing beads can be produced by applying drug to an inert support, e.g., inert sugar beads coated with drug or by creating a "core" comprising both drug and one or more excipients.
  • drug-containing "granules" and “particles” comprise drug particles that may or may not include one or more additional excipients or polymers.
  • granules and particles do not contain an inert support.
  • Granules generally comprise drug particles and require further processing. Generally, particles are smaller than granules, and are not further processed.
  • beads, granules and particles may be formulated to provide immediate release, beads and granules are generally employed to provide delayed release.
  • a first group beads, granules or particles releases drug substantially immediately following ingestion of the dosage form
  • a second group of beads or granules preferably releases drug approximately 3 hours to less than 14 hours following ingestion of the dosage form.
  • a first group of beads, granules or particles releases drug substantially immediately following ingestion of the dosage form
  • a second group of beads or granules preferably releases drug approximately 3 hours to 10 hours following ingestion of the dosage form
  • a third group of beads, granules or particles releases drug at least 5 hours to approximately 18 hours following ingestion of the dosage form.
  • the above-mentioned tablets, beads, granules or particles of different drug release profiles may be mixed and included in a capsule, tablet or matrix to provide a pulsatile dosage form having the desired release profile.
  • the individual dosage units are compacted in a single tablet, and may represent integral but discrete segments thereof (e.g., layers), or may be present as a simple admixture.
  • drug- containing beads, granules or particles with different drug release profiles e.g., immediate and delayed release profiles
  • a dosage form in a further alternative embodiment, comprises an inner drug-containing core and at least one drug-containing layer surrounding the inner core.
  • An outer layer of this dosage form contains an initial, immediate release dose of the drug.
  • the dosage form has an outer layer that releases drug substantially immediately following oral admimstration and an inner core having a polymeric-coating that preferably releases the active agent approximately 3 hours to less than 14 hours following ingestion of the dosage unit.
  • the dosage form has an outer layer that releases drug substantially immediately following oral administration, an inner core that preferably releases drug at least 5 hours to 18 hours following oral administration and a layer interposed between the inner core and outer layer that preferably releases drug approximately 3 hours to 10 hours following ingestion of the dosage form.
  • the inner core of the dosage form mimicking three times daily a dosing may be formulated as compressed delayed release beads or granules.
  • the dosage form has an outer layer and an inner layer free of drug.
  • the outer layer releases drug substantially immediately following oral administration, and completely surrounds the inner layer.
  • the inner layer surrounds both the second and third doses and preferably prevents release of these doses for approximately 3 hours to 10 hours following oral administration.
  • the second dose is immediately available while the third dose is formulated as delayed release beads or granules such that release of the third dose is effected approximately 2 hours to 8 thereafter effectively resulting in release of the third dose at least 5 hours to approximately 18 hours following ingestion of the dosage form.
  • the second and third doses may be formulated by admixing immediate release and delayed release beads, granules or particles and compressing the admixture to form a second and third dose- containing core followed by polymeric coating to achieve the desired three times daily dosing profile.
  • a dosage form comprises a coated core- type delivery system wherein the outer layer is comprised of an immediate release dosage unit, such that active agent therein is immediately release following oral administration, an intermediate layer thereunder surrounds a core, and the core is comprised of immediate release beads or granules and delayed release beads or granules, such that the second dose is provided by the immediate release beads or granules and the third dose is provided by the delayed release beads or granules.
  • Such methods include, but are not limited to, the following: coating a drug or drug-containing composition with an appropriate coating material, typically although not necessarily a incorporating a polymeric material; increasing drug particle size; placing the drug within a matrix; and forming complexes of the drug with a suitable complexing agent.
  • the delayed release dosage units in any of the above embodiments can be prepared, for example, by coating a drug or a drug-containing composition with a selected coating material.
  • the drug-containing composition may be, e.g., a tablet for incorporation into a capsule, a tablet for use as an inner core in a "coated core” dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or capsule.
  • Preferred coating materials are comprised of bioerodible, gradually hydrolyzable, gradually water-soluble, and/or enzymatically degradable polymers, and may be conventional "enteric" polymers.
  • Enteric polymers become soluble in the higher pH environment of the lower gastrointestinal tract or slowly erode as the dosage form passes through the gastrointestinal tract, while enzymatically degradable polymers are degraded by bacterial enzymes present in the lower gastrointestinal tract, particularly in the colon.
  • Suitable coating materials for effecting delayed release include, but are not limited to, cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate, and other methacrylic resins that are commercially available under the tradename Eudragit.RTM.
  • cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose,
  • Eudragits.RTM (Rohm Pharma; Westerstadt, Germany), including Eudragit.RTM. L30D-55 and L100-55 (soluble at pH 5.5 and above), Eudragit.RTM. L-100 (soluble at pH 6.0 and above), Eudragit.RTM. S (soluble at ' pH 7.0 and above, as a result of a higher degree of esterification), and Eudragits.RTM.
  • NE, RL and RS water-insoluble polymers having different degrees of permeability and expandability
  • vinyl polymers and copolymers such as polyvinyl pyrrolidone, vinyl acetate, vinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene- vinyl acetate copolymer
  • enzymatically degradable polymers such as azo polymers, pectin, chitosan, amylose and guar gum
  • shellac shellac.
  • Combinations of different coating materials may also be used. Multi-layer coatings using different polymers may also be applied.
  • the preferred coating weights for particular coating materials may be readily determined by those skilled in the art by evaluating individual release profiles for tablets, beads and granules prepared with different quantities of various coating materials. It is the combination of materials, method and form of application that produce the desired release characteristics, which one can determine only from the clinical studies.
  • the coating composition may include conventional additives, such as plasticizers, pigments, colorants, stabilizing agents, glidants, etc.
  • a plasticizer is normally present to reduce the fragility of the coating, and will generally represent about 10 wt. % to 50 wt. % relative to the dry weight of the polymer.
  • typical plasticizers are, but not limited to, polyethylene glycol, propylene glycol, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl citrate, tributyl citrate, triethyl acetyl citrate, castor oil and acetylated monoglycerides.
  • a stabilizing agent is preferably used to stabilize particles in the dispersion.
  • Typical stabilizing agents are nonionic emulsifiers such as sorbitan esters, polysorbates and polyvinylpyrrolidone. Glidants are recommended to reduce sticking effects during film formation and drying, and will generally represent approximately 25 wt. % to 100 wt. % of the polymer weight in the coating solution.
  • One effective glidant is talc.
  • Other glidants such as magnesium stearate and glycerol monostearates may also be used.
  • Pigments such as titanium dioxide may also be used.
  • Small quantities of an anti- foaming agent such as a silicone (e.g., simethicone), may also be added to the coating composition.
  • the delayed release dosage units may be coated with the delayed release polymer coating using conventional techniques, e.g., using a conventional coating pan, an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like.
  • conventional techniques e.g., using a conventional coating pan, an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like.
  • Pharmaceutical Dosage Forms Tablets, eds. Lieberman et al. (New York: Marcel Dekker, Inc., 1989), and to Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, 6.su ⁇ .th Ed. (Media, PA: Williams & Wilkins, 1995).
  • a delayed release tablet may be formulated by dispersing the drug within a matrix of a suitable material such as a hydrophilic polymer or a fatty compound.
  • the hydrophilic polymers may be comprised of polymers or copolymers of cellulose, cellulose ester, acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, and vinyl or enzymatically degradable polymers or copolymers as described above. These hydrophilic polymers are particularly useful for providing a delayed release matrix.
  • Fatty compounds for use as a matrix material include, but are not limited to, waxes (e.g. carnauba wax) and glycerol tristearate.
  • the immediate release dosage unit of the dosage form i.e., a tablet, a plurality of drug-containing beads, granules or particles, or an outer layer of a coated core dosage form-contains a therapeutically effective quantity of the active agent with conventional pharmaceutical excipients.
  • the immediate release dosage unit may or may not be coated, and may or may not be admixed with the delayed release dosage unit or units (as in an encapsulated mixture of immediate release drug-containing granules, particles or beads and delayed release drug-containing granules or beads).
  • a preferred method for preparing immediate release tablets is by compressing a drug-containing blend, e.g., blend of granules, prepared using a direct blend, wet-granulation or dry-granulation process. Immediate release tablets may also be molded rather than compressed, starting with a moist material containing a suitable water-soluble lubricant. However, preferred tablets herein are manufactured using compression rather than molding.
  • a preferred method for forming immediate release drug-containing blend is to mix drug particles directly with one or more excipients such as diluents (or fillers), binders, disintegrants, lubricants, glidants, colorants or the like.
  • a drug-containing blend may be prepared by using a wet-granulation or dry-granulation processes.
  • Beads containing the active agent may also be prepared by any one of a number of conventional techniques, typically starting from a fluid dispersion.
  • a typical method for preparing drug-containing beads involves blending the active agent with conventional pharmaceutical excipients such as microcrystalline cellulose, starch, polyvinylpyrrolidone, methylcellulose, talc, metallic stearates, silicone dioxide, or the like.
  • the admixture is used to coat a bead core such as a sugar sphere (or so-called "non-pareil”) having a size of approximately 20 to 60 mesh.
  • An alternative procedure for preparing drug beads is by blending drug with one or more pharmaceutically acceptable excipients, such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, a disintegrant, etc., extruding the blend, spheronizing the extrudate, drying and optionally coating to form the immediate release beads.
  • excipients such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, a disintegrant, etc.
  • Optional pharmaceutically acceptable excipients present in the drug- containing tablets, beads, granules or particles include, but are not limited to, diluents, binders, lubricants, disintegrants, colorants, stabilizers, surfactants and the like.
  • Diluents also termed “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules.
  • Suitable diluents include, for example, dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and powder sugar. Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet or bead or granule remains intact after the formation of the dosage forms.
  • Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, cellulose and veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid and polyvinylpyrrolidone.
  • Lubricants are used to facilitate tablet manufacture; examples of suitable lubricants include, for example, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, and polyethylene glycol, talc, and mineral oil.
  • Disintegrants are used to facilitate dosage form disintegration or "breakup" after administration, and are generally starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross-linked PVP (Polyplasdone XL from GAF Chemical Corp).
  • Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way or example, oxidative reactions.
  • Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents. Suitable anionic surfactants include, but not limited to those containing carboxylate, sulfonate and sulfate ions.
  • anionic surfactants are sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2- ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but not limited quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene (15) and coconut amine.
  • nonionic surfactants are, but not limited to, ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene (8) monolaurate, polysorbates, ii polyoxyethylene (9) octylphenylether, PEG-1000 cetyl ether, polyoxyethylene (3) tridecyl ether, polypropylene glycol (18) butyl ether, Poloxamer 401, stearoyl monoisopropanolamide, and polyoxyethylene (5) hydrogenated tallow amide.
  • amphoteric surfactants are, but not limited to, sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the tablets, beads granules or particles may also contain minor amount of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, preservatives, and the like.
  • the amount of active agent released in each dose will be a therapeutically effective amount. In the case of milnacipran, the total amount in the dosage form is in the range of approximately 25 to 500 mg.
  • the total amount of active agent in a dosage form is divided evenly between each pulse contained in the dosage form.
  • the active agent in immediate release form generally represents about 30 wt. % to 70 wt. %, preferably 40 wt. % to 60 wt. %, of the total active agent in one dosage form, while, correspondingly, the active agent in the delayed release form generally represents about 70 wt. % to 30 wt. %, preferably 60 wt. % to 40 wt. %, of the total active agent in one dosage form.
  • the active agent in the immediate release unit(s) and in each of the two delayed release units represents about 20 wt. % to 50 wt. %, preferably 25 wt. % to 40 wt. %, of the total active agent in one dosage form.
  • a kit wherein the once a day pulsatile release dosage form is packaged to provide a method to conveniently begin dose titration at lower doses, for example, beginning at 25mg, gradually increasing to 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, 500 mg, over a period ranging from three days up to 16 weeks.
  • the kit wherein the packaging material may be a box, bottle, blister package, tray, or card.
  • the kit will include a package insert instructing the patient to take a specific dose at a specific time, for example, a first dose on day one, a second higher dose on day two, a third higher dose on day three, and so on, until a maintenance dose is reached.
  • a number of methods are available for preparing drug-containing tablets, beads, granules or particles that provide a variety of drug release profiles. Such methods include, but are not limited to, the following: coating a drug or drug-containing composition with an appropriate coating material, typically although not necessarily incorporating a polymeric material, increasing drug particle size, placing the drug within a matrix, and forming complexes of the drug with a suitable complexing agent.
  • the pulsatile release dosage units may be coated with the delayed release polymer coating using conventional techniques, e.g., using a conventional coating pan, an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like.
  • Milnacipran can be administered for the treatment of depression, for fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS) such as irritable bowel syndrome (IBS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders (major depressive disorder, dysthymia, atypical depression) and anxiety disorders (generalized anxiety disorder, phobias, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder), premenstrual dysphoric disorder, temperomandibular disorder, atypical face pain, migraine headache, and tension headache.
  • IBS irritable bowel syndrome
  • NCCP noncardiac chest pain
  • functional dyspepsia interstitial cystitis
  • essential vulvodynia essential vulvodynia
  • Adverse reactions to the oral administration of milnacipran typically include at least one of the following: nausea, vomiting, headache, dyspepsia, abdominal pain, insomnia, tremulousness, anxiety, panic attack, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, ,dysoria, nervousness, dry mouth, and irritability.
  • the vomiting reflex is triggered by stimulation of chemoreceptors in the upper GI tract and mechanoreceptors in the wall of the GI tract which are activated by both contraction and distension of the gut wall as well as by physical damage.
  • a coordinating center in the central nervous system controls the emetic response. The center is located in the parvicellular reticular formation in the lateral medullary region of the brain.
  • Afferent nerves to the vomiting center arise from the abdominal splanchic and vagal nerves, vestibule-labyrinthine receptors, the cerebral cortex and the cehmoreceptors trigger zone (CTZ).
  • the CTZ lies adjacent in the area postrema and contains chemoreceptors that sample both blood and cerebro spinal fluid.
  • Direct links exist between the emetic center and the CTZ.
  • the CTZ is exposed to emetic stimuli of endogenous origin and to stimuli of exogenous origin such as drugs.
  • the efferent branches of the cranial nerves V, VII, and IX, as well as the vagus nerve and sympathetic trunk produce the complex coordinated set of muscular contractions, cardiovascular responses and reverse peristalsis that characterizes vomiting.
  • the area postrema is rich in dopamine receptors as well as 5-hydroxytryptamine (5HT) receptors.
  • 5HT 5-hydroxytryptamine
  • the pharmaceutical composition of milnacipran provides the in vivo drug plasma levels characterized by the first initial peak plasma concentration ( C max ) below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml that occurs in about 0.05 to about 3 hours after oral administration (first T max ).
  • the second in vivo plasma concentration peak occurs in about 3 to about 14 hours after oral administration (second T max ) and is characterized by C max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.
  • the third, optional, in vivo plasma concentration peak occurs in about 5 to about 18 hours after oral administration (third T max ) and is characterized by C max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.
  • enteric coating When enteric coating is added to the formulation described above, the formulation after oral administration first passes through the stomach releasing less than approximately 10% of the first "pulse” milnacipran dose and then enters the intestines where the remaining portion of the first "pulse” is released.
  • the release profile is characterized by a 0.05-4 hours lag time period during which less than approximately 10% of the first "pulse” milnacipran dose is released followed by a complete release of the first "pulse".
  • enteric coating minimizes direct milnacipran interaction with the stomach mucosa and, thus, further diminishes incidence and reduces intensity of common milnacipran side effects.
  • An enteric coated formulation demonstrates similar in vivo plasma Cmax levels to the uncoated one, but Tmax for the first pulse increases by 0.05-4 hours. T max for the second and the third (optional) pulses may be kept the same as for an uncoated formulation by adjusting the formulation ingredients to meet the desired release profile.
  • This dosage form offers many advantages, when compared to immediate release delivery systems, such as: minimization of peak-trough- fluctuations, avoidance of undesirable side effects and/or lowering their intensity/severity, reduced frequency of administration and improved patient compliance.
  • This formulation is designed to be administered once-a-day to a patient in need thereof, so that milnacipran is delivered over approximately 24 hours, with diminished incidence and decreased intensity of one or more common milnacipran side effects such as nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
  • milnacipran side effects such as nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somno
  • Example 1 Preparation of an Immediate Release Portion of Pulsatile Release Milnacipran Formulation Ingredients, manufacturing process, and tablet parameters for the immediate release portion of the pulsatile release milnacipran pharmaceutical composition (Lot# 1).
  • the formulations were prepared using aqueous media for wet granulation step.
  • Lot# 1 immediate release tablets were used for preparation of enteric coated dosage form.
  • the manufacturing procedure consisted of spraying an aqueous enteric coating suspension onto the immediate release tablets fluidized in the GPCG-1 (Glatt Air Techniques, Inc.). 20% coat weight gain was achieved for Lot# 3.
  • the process parameters were adjusted to accomplish good quality coating.
  • the ingredients of aqueous enteric coating suspension are given below.
  • the final dosage form for pulsatile delivery of milnacipran is prepared by combining in the desired proportion an immediate release portion of the Examples 1 or 2 with a delayed release portion of the Example 4. Different size capsules could be prepared depending on the required daily dose.
  • Example 6 Preparation of an Alternative Pulsatile Release Milnacipran Formulation
  • the final dosage form for pulsatile delivery of milnacipran is prepared by combining in the desired proportion an enteric coated portion of the Example 3 with a delayed release portion of the Example 4. Different size capsules could be prepared depending on the required daily dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition à libération intermittente de milnaciprane s'administrant par voie orale une fois par jour et libérant le médicament en « impulsions » distanciées les unes des autres. Les formes galéniques sont composées d'une première, deuxième et éventuellement, troisième unité galénique, dont chacune possède un profil de libération différent. Cette forme galénique produit des concentrations médicamenteuses plasmiques in vivo caractérisés par Cmax inférieur à 3 000 ng/ml, de préférence, inférieur à 2 000 ng/ml, et, dans un mode de réalisation préféré, inférieur à 1 000 ng/ml. Ces concentrations contribuent à éviter la stimulation des effets cholinergiques sur le système nerveux central. Cette composition permet d'administrer le milnaciprane sur environ 24 heures, ce qui permet de diminuer le nombre ou l'intensité d'effets secondaires communs du milnaciprane, tels que la perturbation du sommeil, la nausée, le vomissement, la migraine, la fébrilité, l'anxiété, les attaques de panique, les palpitations, la rétention urinaire, l'hypotension orthostatique, la diaphorèse, la douleur thoracique, l'éruption cutanée, la prise de poids, les douleurs du dos, la constipation, le vertige, la transpiration excessive, l'agitation, les bouffées de chaleur, les tremblements, la fatigue, la somnolence, la dyspepsie, la dysorie, la nervosité, la sécheresse buccale, les douleurs abdominales, l'irritabilité et l'insomnie.
PCT/US2003/033685 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane WO2004039361A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002503121A CA2503121A1 (fr) 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane
MXPA05004422A MXPA05004422A (es) 2002-10-25 2003-10-22 Composiciones de milnacipran de liberacion pulsatil.
AU2003301762A AU2003301762B2 (en) 2002-10-25 2003-10-22 Pulsatile release compositions of milnacipran
PCT/US2003/033685 WO2004039361A1 (fr) 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane
EP03809957A EP1556024A4 (fr) 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane
JP2005501896A JP2006506461A (ja) 2002-10-25 2003-10-22 ミルナシプランのパルス型放出組成物

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US42164002P 2002-10-25 2002-10-25
US60/421,640 2002-10-25
US43162602P 2002-12-05 2002-12-05
US43162702P 2002-12-05 2002-12-05
US60/431,627 2002-12-05
US60/431,626 2002-12-05
US43190602P 2002-12-09 2002-12-09
US43186102P 2002-12-09 2002-12-09
US60/431,906 2002-12-09
US60/431,861 2002-12-09
US44361803P 2003-01-29 2003-01-29
US60/443,618 2003-01-29
US45906103P 2003-03-28 2003-03-28
US45899503P 2003-03-28 2003-03-28
US45899403P 2003-03-28 2003-03-28
US60/458,995 2003-03-28
US60/458,994 2003-03-28
US60/459,061 2003-03-28
PCT/US2003/033685 WO2004039361A1 (fr) 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane

Publications (1)

Publication Number Publication Date
WO2004039361A1 true WO2004039361A1 (fr) 2004-05-13

Family

ID=36650219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033685 WO2004039361A1 (fr) 2002-10-25 2003-10-22 Compositions a liberation intermittente de milnaciprane

Country Status (6)

Country Link
EP (1) EP1556024A4 (fr)
JP (1) JP2006506461A (fr)
AU (1) AU2003301762B2 (fr)
CA (1) CA2503121A1 (fr)
MX (1) MXPA05004422A (fr)
WO (1) WO2004039361A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578403A4 (fr) * 2002-10-25 2007-01-03 Collegium Pharmaceutical Inc Compositions de milnaciprane a liberation modifiee
WO2007064845A1 (fr) * 2005-11-29 2007-06-07 Pr Pharmaceuticals, Inc. Compositions d'administration de medicaments a butorphanol a liberation prolongee pour analgesie
EP1894565A4 (fr) * 2005-06-10 2009-07-01 Pf Medicament Formule stabilisée de milnacipran
WO2009139504A3 (fr) * 2008-05-15 2010-09-30 Otsuka Pharmaceutical Co., Ltd. Formulation pharmaceutique solide
WO2011107922A2 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Composition de milnacipran à libération prolongée
WO2011107921A2 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Composition de milnacipran à libération modifiée
EP1755682A4 (fr) * 2004-05-20 2012-11-07 Otsuka Pharma Co Ltd Préparation pharmaceutique solide
US8501816B2 (en) 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
US9801827B2 (en) 2006-03-06 2017-10-31 Pozen Inc. Dosage forms for administering combinations of drugs
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
NZ540054A (en) 2002-12-27 2007-09-28 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
EP1993518A4 (fr) * 2006-03-06 2012-12-12 Pozen Inc Formes pharmaceutiques pour l'administration d'associations de medicaments

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759299A1 (fr) 1995-08-16 1997-02-26 Eli Lilly And Company Potentialisation de la sérotonine
WO1998008495A1 (fr) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
WO1999059593A1 (fr) 1998-05-21 1999-11-25 Eli Lilly And Company Therapie combinee destinee au traitement de la depression
WO2000040224A1 (fr) 1999-01-07 2000-07-13 Elan Corporation, Plc Formes posologiques orale multiparticulaires
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1165054A4 (fr) * 1999-04-06 2005-02-09 Pharmaquest Ltd Forme posologique pharmaceutique permettant l'administration intermittente de methylphenidate
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
CA2380333A1 (fr) * 1999-08-26 2001-03-01 Christian Andina Compositions pharmaceutiques
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
JP3797605B2 (ja) * 2002-03-20 2006-07-19 旭化成ファーマ株式会社 粒状被覆製剤の製造方法
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
EP0759299A1 (fr) 1995-08-16 1997-02-26 Eli Lilly And Company Potentialisation de la sérotonine
WO1998008495A1 (fr) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
WO1999059593A1 (fr) 1998-05-21 1999-11-25 Eli Lilly And Company Therapie combinee destinee au traitement de la depression
WO2000040224A1 (fr) 1999-01-07 2000-07-13 Elan Corporation, Plc Formes posologiques orale multiparticulaires
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1556024A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578403A4 (fr) * 2002-10-25 2007-01-03 Collegium Pharmaceutical Inc Compositions de milnaciprane a liberation modifiee
EP1755682A4 (fr) * 2004-05-20 2012-11-07 Otsuka Pharma Co Ltd Préparation pharmaceutique solide
US8821936B2 (en) 2004-05-20 2014-09-02 Otsuka Pharmaceutical Co., Ltd. Solid pharmaceutical formulation
EP1894565A4 (fr) * 2005-06-10 2009-07-01 Pf Medicament Formule stabilisée de milnacipran
US8309128B2 (en) 2005-06-10 2012-11-13 Pierre Fabre Medicament Stabilized milnacipran formulation
WO2007064845A1 (fr) * 2005-11-29 2007-06-07 Pr Pharmaceuticals, Inc. Compositions d'administration de medicaments a butorphanol a liberation prolongee pour analgesie
US9801827B2 (en) 2006-03-06 2017-10-31 Pozen Inc. Dosage forms for administering combinations of drugs
WO2009139504A3 (fr) * 2008-05-15 2010-09-30 Otsuka Pharmaceutical Co., Ltd. Formulation pharmaceutique solide
EA022712B1 (ru) * 2008-05-15 2016-02-29 Оцука Фармасьютикал Ко., Лтд. Твердая фармацевтическая композиция
WO2011107921A3 (fr) * 2010-03-04 2012-07-26 Ranbaxy Laboratories Limited Composition de milnacipran à libération modifiée
WO2011107922A3 (fr) * 2010-03-04 2012-04-26 Ranbaxy Laboratories Limited Composition de milnacipran à libération prolongée
WO2011107921A2 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Composition de milnacipran à libération modifiée
WO2011107922A2 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Composition de milnacipran à libération prolongée
US8501816B2 (en) 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Also Published As

Publication number Publication date
EP1556024A4 (fr) 2007-01-17
EP1556024A1 (fr) 2005-07-27
CA2503121A1 (fr) 2004-05-13
MXPA05004422A (es) 2007-11-22
AU2003301762B2 (en) 2006-02-09
AU2003301762A1 (en) 2004-05-25
JP2006506461A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
AU2003301671B2 (en) Modified release compositions of milnacipran
US7704527B2 (en) Modified release compositions of milnacipran
EP1833467B1 (fr) Compositions pharmaceutiques destinees a des troubles du sommeil
JP2006503918A5 (fr)
AU2004207578B2 (en) Multiparticulate compositions of milnacipran for oral administration
AU2003301762B2 (en) Pulsatile release compositions of milnacipran
US20080085312A1 (en) Multi-Phase Release Potassium Guaiacolsulfonate Compositions
US20100063084A1 (en) Multi-phase release methscopolamine compositions
US20060024366A1 (en) Modified release compositions of milnacipran
US20060003004A1 (en) Pulsatile release compositions of milnacipran
US20100286260A1 (en) Milnacipran formulations
JP2009511607A (ja) エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003301762

Country of ref document: AU

Ref document number: 1572/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2503121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005501896

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004422

Country of ref document: MX

Ref document number: 2003809957

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003809957

Country of ref document: EP